Patent Application
20050043551
This invention is related with the animal and human sector particularly with a product having a potent anticoccidial activity. It has been shown very satisfactory results in experimentation and industrial exploitation animals used as a source of foods.
Previous Technique
It has been reported, in scientific articles and in information patents that furan products, particularly nitrofuran compounds, show action against Coccidia. In spite of the fact that these compounds are still available in the market, their consumption have been diminishing because they have toxic properties with the position of the nitro group in the carbon 5 of the furan ring. These products are furazolidone. (FUROBAC) and nitrofurazone, among others.
(FUROBAC http://terra.com.mx/-rcamacho/ges/ges-furo.html), Environmental Mutagenesis 5: 745-765 (1983), Com.Reg. 19.03.92 (L73), Com.Reg. 15.10.93 (L 264)
The obtention of 2-(2-nitrovynil)-furan as a chemical entity has been reported earlier only at laboratory level, and these are not antecedents of their use as human or animal medication. Its synthesis has not been reported in any case as active principle with pharmaceutical quality.
The purity of the compound has not been reported in the literature describing its synthesis at the laboratory level, which prevent from evaluating if it fulfills those requirements needed to be used as medication. Neither the studies on the reproducibility of the results in the syntheses, nor the reactions to scales different from those at molar fractions are reported, as can be appreciated in the following references:
There are also some patents where 2-(2-nitrovynil)-furan is used as part of synergic mixtures for industrial antimicrobial applications, but they do not describe aspects related with its synthesis. Among others they are the patents of the North American Company Great Lakes Chemical Co. (U.S. Pat. No. 5,416,107; U.S. Pat. No. 5,416,108; U.S. Pat. No. 5,358,963; U.S. Pat. No. 5,246,963 and WO 94/02017).
“Popularization” of the Invention
This invention is based on a simple compound of furan base, 2-(2-nitrovynil)-furan, which presents a nitro group in its structure, but not in the position 5 of the ring but in the double exociclic bond. It has been corroborated through predictive and experimental methods that this variation in the position of the nitro group in this family modifies favorably both its pharmacological and toxicological properties.
This invention also includes a new procedure for obtaining 2-(2-nitrovynil)-furan, which consists of reacting the nitromethane and the furfural in presence of ethanol in molar reactions 1: 1 to 1: 2.5, during 3 to 5 hours, in a range of temperatures between 110 and 130° C., using from 1 to 2.5 ml of isobutyl amine (IBA) per mol of furfural, with a speed of agitation between 100 and 400 rpm. The condenser of the reaction equipment is connected to absorption traps containing water to absorb nitrous gases to avoid the environmental contamination.
The reaction mixture obtained in those conditions undergoes a process of “cooling” between −15 +10C. Then the solid is separated by means of a process of centrifugation or filtration in vacuum.
The raw product becomes purified dissolving it in 4 to 10 volumes of ethanol at a temperature between 40 and 65° C. during 10 to 30 minutes, with 5 to 25% of activated coal. Later it is filtered on activated coal and allowed to precipitate of a temperature between −15 and 10° C. Then, the pure product is filtered dried off in a stove at vacuum during 1 to 3.5 hours at a temperature that oscillates between 20 and 50° C. and stored at a temperature between 10 and 20° C.
By means of the procedure of this invention, which is executed at the moment at pilot plant scale, the 2-(2-nitrovynil)-furan is obtained in form of yellow crystals with a fusion temperature of 74-75 Celsius degrees, with high yields and purity that surpass the 99%, which permit the use of this active principle in the pharmaceutical industry. The structural analysis of this product was performed with the use of all modern spectroscopic techniques.
The concentration of 2-(2-nitrovynil)-furan in the pharmaceutical composition, for its use in the treatment of Coccidia in human and veterinary medicine, oscillates in a range between 2 and 80 ppm.
Toxicological studies, necessary to perform studies of effectiveness of the product, showed that the Half Lethal Dose (LD50) for oral route of 2-(2-nitrovynil)-furan using several solvents, was 1.02 g/kg of body mass for mature Leghorn hens and 171.91 mg/kg of body mass for females and males Sprague Dawley rats.
In vitro mutagenesis studies were carried out using the micronucleus assay with blockade of cytokinesis with and without metabolic activation, as well as the sister chromatide exchange assay with and without metabolic activation. It was are carried out a theoretical study assisted by computer for the prognosis of the mutagenic activity. In all those 2-(2-nitrovynil)-furan did not shown mutagenic activity.
In order to evaluate the effectiveness against Coccidia from several animal species, artificial infection experiments of Eimeria tenella in poultry, as well as in high naturally infected chicken with this protozoa were carried out. The effect against the intestinal Coccidia of artificially and naturally infected rabbits was also evaluated the last in conditions of production.
Examples of the realization of this invention are fallow described.
Synthesis of 2-(2-nitrovynil)-furan was carried out by means of the procedure of the invention, varying several parameters inside the reported ranges. Table 1 shows the degrees of purity obtained in the synthesis of 2-(2-nitrovynil)-furan carried out in 6 liters reactors, under different assayed conditions.
(*) The determination of the purity percent was carried out by means of HPLC.
To carried out the assay of the action of the synthesized product, the 2-(2nitrovynil)-furan, it was first dissolved first in an alcoholic solution at 3% and later in water, using several concentrations (2, 4, 8 μg/ml) of the alcohol-water solution, as is shown Table 2.
One day old, male, free of Coccidia, F1 fatten chicks were used. These birds were maintained in an appropriate condition, free of Coccidia until two weeks of age. For feeding, it was used the same food used to fatten chickens but free of anticoccididals.
5 groups of 12 poultry with similar weight were formed which received an inoculation of 1×105 oocysts of Eimeria tenella by oral route, using a esophagic canula. The treatment began when chicks had 15 days of age, 24 hours before receiving the inoculation, during a period of 9 days.
To evaluate the effectiveness of the product the gain of weight (% referred to the initial weight) and the death number approaches were used in each tratment. The results are shown in Table 2.
As be observed, satisfactory results were obtained at a concentration of 4 μg/ml, where there were no deaths and the weight gain was very similar to the control group, without inoculating.
The 2-(2-nitrovynil)-furan, in a formulation similar to that described in the example 2, was applied, in the drinking water twice a day (8 am and 12 m) for 5 days, to 2000 Leghorn egg-laying hens of 56-84 days of age, infected naturally with E. tenella. Two houses highly infected by caecal coccidiosis with 2000 birds each were there was an average of 119 deaths per house in 5 days were selected. The diagnoses was made by the presence of bloody diarrheas, the observation of typical lesions in the blind intestine and abundant presence of parasite oocysts in the caecal content. Infected birds in a house was left as nontreated control and another no infected as neither infected nor treated control having the same range of age.
To evaluate the effectiveness of the product the approach described in the example 2 was used, except that as weight control. Except that as weight control 10 birds of each pen were randomly selected and weighed at the beginning and the end of the treatment. The obtained results are shown in table 3.
It can be observed that for the dose of 4 μg/ml there was a remarkable decrease of mortality without any weight loss when compared with the affected no treated group.
The 2-(2-nitrovynil)-furan, in a formulation similar to that described in the example 2, was dissolved in rabbits' drinking water and administered daily at libitum for 5 days. Two experiments (I, II), each one with 9 rabbits, were carried out. Each experiment had 3 treatments of 3 animals each one. Among treatments an infected no treated group and a group neither infected nor treated were considered.. In the 1st experiment each rabbit received 61×103 those of the 2nd experiment 116×103 oocysts of intestinal Coccidias. The present species were E. perforans 38%, E. magna 30%, E. media 22% and E. exigua 10%, with a 97.3% of sporulation. The initial and final weight difference and the deaths of animals after 7 days treatment was used as evaluation criteria.
The obtained results are shown in table 4 and 5:
After inoculating 61×103 oocysts there was no mortality at the dose of 4 μg/mL and there was difference with the inoculated without treatment weight group in gain. When 116×103 ocysts were inoculated with the dose of 4 μg/ml there were no deaths and also weight gain was present. Already at this concentration there were deaths in the inoculated without treatment.
The 2-(2-nitrovynil)-furan, in a formulation similar to that described in the example 2, was dissolved in rabbit's drinking water and administered daily at libitum for 5 days at concentration of 4 μg/ml. It were treated 1 246 newborn, young and adult rabbits of the Chinchilla, New White Zelanda and New Red Zelanda species belonging to 3 rabbit companies. The species of Coccidia present were E. perforans 34%, E. magna 32%, E. media 23% and E. exigua 11%. The amount of oocysts per gram of feces before and after 7 days of the treatment was determined to 20% of all treated animals. The difference between the number of oocysts before and after 7 days of treatment expressed as percentage of oocyst reduction, was taken as efficacy criterium.
The obtained results are shown in table 6.
From the results obtained in the experiment, it could be assumed that in a relatively number of animals there was an average reduction of oocyst of 97%. In fact, in a company it was of a 99%, which is a very satisfactory result.
| Number | Date | Country | Kind |
|---|---|---|---|
| 219/01 | Sep 2001 | CU | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CU02/00007 | 9/24/2002 | WO |
